Ibrahimagic Omer C, Smajlovic Dzevdet, Dostovic Zikrija, Pasic Zejneba, Kunic Suljo, Iljazovic Amra, Hajdarevic Denisa Salihovic
Department of Neurology, University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina.
Mater Sociomed. 2016 Jul 24;28(4):303-306. doi: 10.5455/msm.2016.28.303-306.
Homocysteine is process-product of methionine demethylation. It has proatherogenic, prothrombotic, prooxidative, proapoptotic, osteoporotic, neurotoxic, neuroinflamatory, and neurodegenerative effects. Hyperhomocysteinemia correlates with C667T MTHFR mutation, decrease of folic acid and vitamin B, as well as prolonged use of certain medications.
We measured levels of homocysteine in thirty patients (15::15) with "de novo" Parkinson's disease, with average age 64.17 ± 13.19 (28-82) years (Department of Neurology, University Clinical Center Tuzla). Normal level of homocysteine for women was 3.36-20.44 micromole/l and 5.9-16 micromole/l for men. We followed the effects of medicament approach (folic acid) every six months for next five years.
20% of patients with "de novo" Parkinson's disease exhibited hyperhomocysteinemia. An average level of homocysteine was 13.85 ± 5.82 micromole/l. Differences due to age and homocysteine levels, regardless of sex, were not concluded. For the next five years intake of folic acid (periodically, 1-2 months, 5 mg per day, orally) was effective to normalized levels of homocysteine in all.
Hyperhomocysteinemia is present in every fifth patient with "de novo" Parkinson's disease. Folic acid is medication of choice in treatment of hyperhomocysteinemia coexisting with Parkinson's disease.
同型半胱氨酸是蛋氨酸去甲基化的过程产物。它具有促动脉粥样硬化、促血栓形成、促氧化、促凋亡、致骨质疏松、神经毒性、神经炎症和神经退行性变等作用。高同型半胱氨酸血症与C667T亚甲基四氢叶酸还原酶（MTHFR）突变、叶酸和维生素B缺乏以及长期使用某些药物有关。
我们测量了图兹拉大学临床中心神经科30例（15例男性∶15例女性）新发帕金森病患者的同型半胱氨酸水平，平均年龄64.17±13.19（28 - 82）岁。女性同型半胱氨酸正常水平为3.36 - 20.44微摩尔/升，男性为5.9 - 16微摩尔/升。在接下来的五年中，我们每六个月观察一次药物治疗（叶酸）的效果。
20%的新发帕金森病患者表现出高同型半胱氨酸血症。同型半胱氨酸平均水平为13.85±5.82微摩尔/升。未得出年龄和同型半胱氨酸水平之间存在差异，且与性别无关。在接下来的五年中，定期（每1 - 2个月）口服5毫克叶酸，可有效使所有人的同型半胱氨酸水平恢复正常。
每五分之一的新发帕金森病患者存在高同型半胱氨酸血症。叶酸是治疗与帕金森病并存的高同型半胱氨酸血症的首选药物。
